Neutrophil–Platelet and Monocyte–Platelet Aggregates in COVID-19 Patients
Résumé
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the world. Besides severe pneumonia with acute respiratory distress syndrome (ARDS), it has been more recently highlighted that SARS-CoV-2 could predispose to thrombotic disease, both in venous and arterial circulations.[1] Lung autopsy from severe COVID-19 patients revealed high recruitment of innate immune cells including neutrophils and macrophages contributing to the cytokine storm as well as microthrombi.[2] Given the central role of platelets in inflammation and thrombosis, and more specifically leucocyte–platelet aggregates that have been implicated in arterial and venous thrombosis, we aimed to explore neutrophil–platelet aggregate (NPA) and monocyte–platelet aggregate (MPA) in patients hospitalized in a medical ward for COVID-19 infection.
Mots clés
COVID-19 SARS-CoV-2 Platelets Neutrophils Monocytes Leukocytes-Platelets aggregates thrombosis interleukin 6 receptor WORD COUNT :1197 References 25
Table 1
Figure 1
COVID-19
SARS-CoV-2
Platelets
Neutrophils
Monocytes
Leukocytes-Platelets aggregates
thrombosis
interleukin 6 receptor WORD COUNT :1197
References 25
COVID-19 SARS-CoV-2 Platelets Neutrophils Monocytes Leukocytes-Platelets aggregates thrombosis interleukin 6 receptor WORD COUNT :1197 References 25
Domaines
Immunologie
Fichier principal
MANUSCRIPT_LPA_COVID_Letter_R_LM.pdf_1708_TrackChanges.pdf (397.6 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|